Functional genomics in pharmaceutical drug discovery

Handbook of Experimental Pharmacology

Volumn 232, Issue , 2016, Pages 25-41

  Adams, Robert ^a   Steckel, Michael ^a   Nicke, Barbara ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

CRISPR Cas9; Functional genomics; High content assay; High throughput screening; RNA interference (RNAi); Short hairpin RNA (shRNA); Short interfering RNA (siRNA)

Indexed keywords

CASPASE 9; DOUBLE STRANDED RNA; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; B SCORE; BIOINFORMATICS; CANCER CELL LINE; CELL PROLIFERATION; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA LIBRARY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; EFFECT SIZE; FLUORESCENCE ACTIVATED CELL SORTING; FUNCTIONAL GENOMICS; GENETIC SCREENING; GENETIC TRANSFECTION; HIGH CONTENT SCREENING; HUMAN; LETHALITY; NEXT GENERATION SEQUENCING; NONHUMAN; ONCOGENE K RAS; PERFORMANCE; PLASMID; PLATE BASED SCREENING; PRIORITY JOURNAL; PROTEIN TARGETING; RNA EDITING; RNA INTERFERENCE; RNA TRANSLATION; SEQUENCE HOMOLOGY; STATISTICS; STRICTLY STANDARDIZED MEAN DIFFERENCE; VIRAL GENE DELIVERY SYSTEM; Z SCORE; DRUG DEVELOPMENT; GENOMICS; HIGH THROUGHPUT SEQUENCING;

DRUG DISCOVERY; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; RNA INTERFERENCE;

EID: 84962644729     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2015_27     Document Type: Chapter

References (47)

1. Ameres SL, Martinez J, Schroeder R (2007) Cell 130:101-112
2. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607
3. Bassik MC, Lebbink RJ, Churchman LS, Ingolia NT, Patena W, LeProust EM, Schuldiner M, Weissman JS, McManus MT (2009) Rapid creation and quantitative monitoring of high coverage shRNA libraries. Nat Methods 6:443-445
4. Bernards R, Brummelkamp TR, Beijersbergen RL (2006) shRNA libraries and their use in cancer genetics. Nature Methods 3:701-706
5. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS, Khvorova A (2006) 30 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3:199-204
6. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, Santoyo-Lopez J, Dunican DJ, Long A, Kelleher D, Smith Q, Beijersbergen RL, Ghazal P, Shamu CE (2009) Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 6:569-575
7. Boutros M, Ahringer J (2008) The art and design of genetic screens: RNA interference. Nat Rev Genet 9:554-566
8. Brideau C, Gunter B, Pikounis B, Liaw A (2003) Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen 8:634-647
9. Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550-553
10. Buehler E, Chen YC, Martin S (2012a) C911: a bench-level control for sequence specific siRNA off-target effects. PLoS One 7:14
11. Buehler E, Khan AA, Marine S, Rajaram M, Bahl A, Burchard J, Ferrer M (2012b) siRNA offtarget effects in genome-wide screens identify signaling pathway members. Sci Rep 2:428
12. Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB, Jaenisch R (2013) Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell Res 23:1163-1171
13. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R, Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC (2011) Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 108:12372-12377
14. Diehl P, Tedesco D, Chenchik A (2014) Use of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions. Drug Discov Today Technol 11:11-18
15. Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE (2014) Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol 32:1262-1267
16. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498
17. Fehrmann RS, Karjalainen JM, Krajewska M, Westra HJ, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HH, de Vries EG, Te Meerman GJ, Wijmenga C, van Vugt MA, Franke L (2015) Gene expression analysis identifies global gene dosage sensitivity in cancer. Nat Genet 47:115-125
18. Fennell M, Xiang Q, Hwang A, Chen C, Huang C-H, Chen C-C, Pelossof R, Garippa RJ (2014) Impact of RNA-guided technologies for target identification and deconvolution. J Biomol Screen 19:1327-1337
19. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811
20. Gilbert Luke A, Horlbeck Max A, Adamson B, Villalta Jacqueline E, Chen Y, Whitehead Evan H, Guimaraes C, Panning B, Ploegh Hidde L, Bassik Michael C, Qi Lei S, Kampmann M, Weissman Jonathan S (2014) Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159:647-661
21. Grimm S (2004) The art and design of genetic screens: mammalian culture cells. Nat Rev Genet 5:179-189
22. Guilinger JP, Thompson DB, Liu DR (2014) Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechol 32:577-582
23. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CW (2014) ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20:251-254
24. Hendel A, Fine EJ, Bao G, Porteus MH (2015) Quantifying on-and off-target genome editing. Trends Biotechnol 33:132-140
25. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635-637
26. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J (2013) RNA-programmed genome editing in human cells. Elife 29:00471
27. Khan AA, Betel D, Miller ML, Sander C, Leslie CS, Marks DS (2009) Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 27:549-555
28. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM (2013) RNA-guided human genome engineering via Cas9. Science 339:823-826
29. Martin SE, Caplen NJ (2007) Annu Rev Genomics Hum Genet 8:81-108
30. McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA (2002) Gene silencing using micro-RNA designed hairpins. RNA 8:842-850
31. Mohr SE, Smith JA, Shamu CE, Neumuller RA, Perrimon N (2014) RNAi screening comes of age: improved techniques and complementary approaches. Nat Rev Mol Cell Biol 15:591-600
32. Moore JD (2015) The impact of CRISPR-Cas9 on target identification and validation. Drug Discov Today 20(4):450-457
33. Napoli C, Lemieux C, Jorgensen R (1990) Introduction of a chimeric chalcone synthase gene into petunia results in reversible Co-suppression of homologous genes in trans. Plant Cell 2:279-289
34. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948-958
35. Patel AC (2013) Clinical relevance of target identity and biology: implications for drug discovery and development. J Biomol Screen 18:1164-1185
36. Pelz O, Gilsdorf M, Boutros M (2010) Web cellHTS2: a web-application for the analysis of highthroughput screening data. BMC Bioinformatics 11:1471-2105
37. Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32:347-355
38. Sanjana NE, Shalem O, Zhang F (2014) Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11:783-784
39. Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343:84-87
40. Sigoillot FD, King RW (2011) Vigilance and validation: keys to success in RNAi screening. ACS Chem Biol 6:47-60
41. Sigoillot FD, Lyman S, Huckins JF, Adamson B, Chung E, Quattrochi B, King RW (2012) A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens. Nat Methods 9(4):363-366
42. Surendranath V, Theis M, Habermann BH, Buchholz F (2013) Designing efficient and specific endoribonuclease-prepared siRNAs. Methods Mol Biol 942:193-204
43. Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 342:80-84
44. Weinstein IB (2002) Cancer. Addiction to oncogenes-the Achilles heel of cancer. Science 297:63-64
45. Wenzel C, Riefke B, Grundemann S, Krebs A, Christian S, Prinz F, Osterland M, Golfier S, Rase S, Ansari N, Esner M, Bickle M, Pampaloni F, Mattheyer C, Stelzer EH, Parczyk K, Prechtl S, Steigemann P (2014) 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res 323:131-143
46. Wilson BG, Helming KC, Wang X, Kim Y, Vazquez F, Jagani Z, Hahn WC, Roberts CW (2014) Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol 34:1136-1144
47. Zhou Y, Zhu S, Cai C, Yuan P, Li C, Huang Y, Wei W (2014) High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509:487-491